

Appointment of New Non-Executive Director

5 June 2020, Melbourne: Rhythm Biosciences Limited (ASX: RHY or "Rhythm") is pleased to announce the appointment of Mr Eduardo Vom as a Non-Executive Director of the Company.

Mr Vom is a Co-Founder and Executive Director of Planet Innovation, a technology development and commercialisation company, and 3 times winner of The Australian Financial Review's Most Innovative Companies. He has a long association with RHY, being a shareholder and through his involvement as an advisor during the Company's inception.

Mr Vom has over 20 years' experience in technology development and commercialisation in the biotech industry, having held leadership roles at cancer diagnostics manufacturer Vision BioSystems and molecular diagnostics company Genetic Technologies. He also currently serves as a non-executive director with privately owned health and wellbeing companies and is well known for his expertise in digital healthcare, management of multi discipline projects, business strategy and technology commercialisation. Mr Vom holds a Post Graduate Diploma in Management Technology and an honours degree in Industrial Engineering and Computing from Monash University.

Non-Executive Chairman of RHY, Mr Otto Buttula, said, "We are pleased to secure a non-executive director of Eduardo's calibre to the Board. His proven capabilities in delivering results coupled with his intimate knowledge of Rhythm's technology and the Company's origins is an important addition. I welcome Eduardo to Rhythm and the Board and look forward to working with him to advance our ambition to become a globally significant developer of mass market screening technology for the early detection of colorectal cancer."

Mr Vom added "I look forward to joining Rhythm at a pivotal moment in the Company's development. I have been an investor from the start, following closely the significant advancements made since the Company began commercialising the technology originally developed by the CSIRO. We have a massive opportunity here with global relevance, not only to save lives, but to influence the overall quality of people's lives. That is something I want to be a part of."

Rhythm continues to progress the development of the optimisation program aimed at validating its proprietary version of antibodies which will be combined in the ColoSTAT® test. The global unmet need for a mass market, affordable and non-invasive screening test remains unchanged. The development of the Company's simple blood test, ColoSTAT®, has the potential to be a worldwide diagnostic tool of choice for the early detection of colorectal cancer.

Rhythm BiosciencesACN: 619 459 335
ASX: RHY**Issued Capital**100,750,000 Shares
3,000,000 Options**Australian Registered Office**Level 17, 500 Collins Street
Melbourne VIC 3000
www.rhythmbio.com**Directors**Otto Buttula – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
David John White – Non-Executive Director
Eduardo Vom – Non-Executive Director

In accordance with Listing Rule 3.19A, attached is Appendix 3X, an initial Director's Interest Notice for Mr Eduardo Vom.

With the authority of the Board.

For further information, please contact:

Adrien Wing
Company Secretary
Ph: +61 3 9614 0600

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Rhythm Biosciences Limited
ABN	59 619 459 335

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Eduardo Vom
Date of appointment	5 June 2020

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Eduardo Vom - 710,000 fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3X Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.	
Natalie Patterson (spouse)	2,000,000 fully paid ordinary shares

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.